Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Infection

Interventions

DRUG: lopinavir/ritonavir (LPV/r)
DRUG: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
DRUG: raltegravir (RAL)

Sponsor

Abbott

Collaborators

[object Object]